Patents by Inventor Brett Lauring

Brett Lauring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES
    Publication number: 20240115587
    Abstract: This disclosure is directed, at least in part, to combination therapies comprising GPR119 agonists and GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the condition or disorder is: a metabolic disorder, such as diabetes, obesity, or nonalcoholic steatohepatitis (NASH); a nutritional disorder, such as short bowel syndrome; or an eating disorder, such as binge eating disorder.
    Type: Application
    Filed: November 6, 2023
    Publication date: April 11, 2024
    Inventors: Shirly PINTO, Iyassu SEBHAT, Brett LAURING, Nancy A. THORNBERRY
  • AMPK ACTIVATORS
    Publication number: 20240101558
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 28, 2024
    Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
  • AMPK activators
    Patent number: 11851429
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 26, 2023
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Ann Weber, Nancy Thornberry, Lisa Krug, Paul Richards, Brett Lauring
  • AMPK ACTIVATORS
    Publication number: 20220227754
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Application
    Filed: January 26, 2022
    Publication date: July 21, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
  • AMPK ACTIVATORS
    Publication number: 20220033401
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
  • METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELTED DISEASES USING SGLT-2 INHIBITORS
    Publication number: 20200038368
    Abstract: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Applicants: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Brett Lauring, Samuel S. Engel, Steven G. Terra, James M. Rusnak
  • METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS
    Publication number: 20190076395
    Abstract: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
    Type: Application
    Filed: March 6, 2017
    Publication date: March 14, 2019
    Applicants: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Brett LAURING, Samuel S. ENGEL, Steven G. TERRA, James M. RUSNAK
  • METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR
    Publication number: 20140323497
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: November 12, 2013
    Publication date: October 30, 2014
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margeiefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
  • METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR
    Publication number: 20120095019
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: August 31, 2011
    Publication date: April 19, 2012
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey